Bradykinin and Pain

  • Solomon H. Snyder
  • Donald C. Manning
  • Larry R. Steranka


Basic biomedical research attempts to understand bodily functions, but the implicit or explicit underlying assumption is that new information is being sought so as to discover more effective and safer therapies. How does molecular research into the addictive processes fit into this model? Addiction takes place to a wide variety of psychoactive substances, all of which seem to share the capacity to provide behavioral reinforcement, some enhanced sense of well-being, or euphoria. Along with their sedative effects, alcohol and barbiturates provoke euphoria in susceptible individuals. The stimulant actions of cocaine and amphetamines might in principle have therapeutic actions except for the addictive propensity associated with the euphoric actions of the drugs. Similarly, opiates, besides providing analgesia, elicit reinforcing subjective effects. The phenomena of tolerance, physical dependence, and compulsive drug-seeking behavior are common to addiction involving all of the dependence-producing substances. Because of the similarity in formal properties of the addictive process across different drug classes, it is conceivable that the same or closely similar general mechanism is involved in addiction to all drugs, although each utilizes distinct neurochemical mediators. Viewed optimistically, if one could solve the riddle of addiction to one substance, then the mystery of addiction for all classes of drugs would be revealed. From a more pessimistic vantage point, one might be concerned that most, if not all, agents that make us “feel good” seem to have abuse liability if not the capacity to cause serious addiction. In principle, sedating, antianxiety, stimulant, and central analgesic drug actions might be elicited by chemicals without provoking the enhanced sense of well-being that seems linked to abuse potential. However, up to the present time virtually all centrally acting drugs that convey these potentially therapeutic actions present addictive liabilities.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Henriques FC, Jr (1947). The predictability and the significance of thermally induced rate processes leading to irreversible epidermal injury. Arch Path 43: 489–502.PubMedGoogle Scholar
  2. 2.
    Hardy JD, Wolff HG, Goodell H (1952). Pain Sensation and Reactions. Williams & Wilkins, Baltimore.Google Scholar
  3. 3.
    Moncada S, Ferreira SH, Vane JR (1978). Pain and inflammatory mediators. In JR Vane, SH Ferreira, eds. Handbook of Experimental Pharmacology. Springer-Verlag, New York pp 588–616.Google Scholar
  4. 4.
    Johnson AR, Erdos EG (1973). Release of histamine from mast cells by vasoactive peptides. Proc Soc Exp Biol Med 142: 1252–1256.PubMedGoogle Scholar
  5. 5.
    Olsson Y (1967). Degranulation of mast cells in peripheral nerve injuries. Acta Neurol Scand 43: 365–374.PubMedCrossRefGoogle Scholar
  6. 6.
    Olsson Y (1968). Mast cells in the nervous system. In GH Bourne, JF Danielli, KW Jeon. eds. International Review of Cytology. Academic Press, Orlando, FL, pp 27–70.Google Scholar
  7. 7.
    Nennesmo I, Reinholt F (1986). Mast cells in nerve end neuromas of mice. Neurosci Lett 69, 296–301.PubMedCrossRefGoogle Scholar
  8. 8.
    Dale, HH (1935). Proc Roy Soc B 28: 319–332.Google Scholar
  9. 9.
    Lewis T, Hess W (1933). Pain derived from the skin and the mechanism of its production. Clin Sci 1: 39–61.Google Scholar
  10. 10.
    LaMotte RH, Simone DA, Baumann TK, Shain CN, Alreja M (1987). Hypothesis for novel classes of chemoreceptors mediating chemogenic pain and itch. Pain [SupplJ 4: S15.CrossRefGoogle Scholar
  11. 10.
    LaMotte RH, Simone DA, Baumann TK, Shain CN, Alreja M (1987). Hypothesis for novel classes of chemoreceptors mediating chemogenic pain and itch. Pain [SupplJ 4: S15.CrossRefGoogle Scholar
  12. 12.
    LaMotte RH, Simone DA, Ngeow JYF, Whitehouse J, Becerra-Cabal L, Putterman GJ (1987). The magnitude and duration of itch produced by intracutaneous injections of histamine. Somatosensory Res 5: 81–92.CrossRefGoogle Scholar
  13. 13.
    Hougs W, Skouby AP (1957). The analgenic action of analgetics, antihistaminics and chlorpromazine on volunteers. Acta Pharmacol Toxicol 13: 405–409.CrossRefGoogle Scholar
  14. 14.
    Richardson BP, Engel G, Donatsch P, Stadler PA (1985). Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs Nature (London) 316: 126–131.CrossRefGoogle Scholar
  15. 15.
    Mense S (1981). Sensitization of group IV muscle receptors to bradykinin by 5-hydroxytryptamine and prostaglandin E2. Brain Res 225: 95–105.PubMedCrossRefGoogle Scholar
  16. 16.
    Hiss E, Mense S (1976). Evidence for the existence of different receptor sites for algesic agents at the endings of muscular group IV afferent units. Pflueger Arch 362: 141–146.CrossRefGoogle Scholar
  17. 17.
    Richardson BP, Engel G (1986). The pharmacology and function of 5-HT3 receptors. Trends Neurosci 9: 424.CrossRefGoogle Scholar
  18. 18.
    Lembeck F, Gamse R (1982). Substance P in peripheral sensory processes. Ciba Found Symp 91: 35.PubMedGoogle Scholar
  19. 19.
    Henry JL (1976). Effects of substance P on functionally identified units in cat spinal cord. Brain Res 114: 439–451.PubMedCrossRefGoogle Scholar
  20. 20.
    Ebertz JM, Hirshman CA, Kettelkamp NS, Uno H, Hanifin JM (1987). Substance P-induced histamine release in human cutaneous mast cells. J Invest Derm 88: 682–685.PubMedCrossRefGoogle Scholar
  21. 21.
    Hagermark O, Hokfelt T, Pernow B (1978). Flare and itch induced by substance P in human skin. J Invest Derm 71: 233–235.PubMedCrossRefGoogle Scholar
  22. 22.
    Barnes PJ, Brown MJ, Dollery CT, Fuller RW, Heavey DJ, Ind PW (1986). Histamine is released from skin by substance P but does not act as the final vasodilator in the axon reflex. Br J Pharmacol 88: 741–745.PubMedGoogle Scholar
  23. 23.
    Brain SD, Tippins JR, Morris HR, Maclntyre I, Williams T (1986). Potent vasodilator activity of calcitonin gene-related peptide in human skin. J Invest Derm 87: 533–536.PubMedCrossRefGoogle Scholar
  24. 24.
    Piotrowski W, Foreman JC (1986). Some effects of calcitonin gene-related peptide in human skin and on histamine release. Br J Derm 114: 37–46.CrossRefGoogle Scholar
  25. 25.
    Kotani Y, Oka M, Yonehara N, Kudo T, Inoki R (1981). Algesiogenic and analgesic activities of synthetic substance P. Jpn J Pharmacol 31: 315–321.PubMedCrossRefGoogle Scholar
  26. 26.
    Lembeck F, Gamse R (1977). Lack of algesic effect of substance P on paravascular pain receptors. Naunyn Schmiedeberg Arch Pharmacol 299: 295–303.CrossRefGoogle Scholar
  27. 27.
    Ferreira SH (1985). Prostaglandin hyperalgesia and the control of inflammatory pain. In IL Bonta, MA Bray, MJ Parnham, eds. Handbook of Inflammation: The Pharmacology of Inflammation. Elsevier, New York pp 107–116.Google Scholar
  28. 28.
    Handwerker HO (1976). Influences of algogenic substances and prostaglandins on the discharges of unmyelinated cutaneous nerve fibers identified as nociceptors. In B Bromm, DG Albe-Fessard, eds. Advances in Pain Research and Therapy, vol 1, Raven Press, New York, pp 41–51.Google Scholar
  29. 29.
    Handwerker HO (1976). Pharmacological modulation of the discharge of nociceptive C fibers. In Y Zotterman, ed. Sensory Functions of the Skin in Primates. ( Pergamon, New York, pp 427–439.Google Scholar
  30. 30.
    Handwerker HO (1976). Influences of algogenic substances and prostaglandins on the discharges of unmyelinated cutaneous nerve fibers identified as nociceptors. In JJ Bonica, D Albe-Fessard, eds. Advances in Pain Research and Therapy, vol 1. Raven Press, New York, pp 41–45.Google Scholar
  31. 31.
    Moncada S, Ferreira SH, Vane JR (1975). Inhibition of prostaglandin biosynthesis as the mechanism of analgesia of aspirin-like drugs in the dog knee joint. Eur J Pharmacol 31: 250–260.PubMedCrossRefGoogle Scholar
  32. 32.
    DiRosa M, Giroud JP, Willoughby DA (1971). Studies of the mediators of the acute inflammatory response induced in rats in different sites by carrageenan and turpentine. J Path 104: 15–29.CrossRefGoogle Scholar
  33. 33.
    Melmon KL, Webster ME, Goldfinger SE, Seegmiller JE (1967). The presence of a kinin in inflammatory synovial effusion from arthritides of varying etiologies. Arthritis Rheum 10: 13–20.PubMedCrossRefGoogle Scholar
  34. 34.
    Coffman JD (1966). The effect of aspirin on pain and hand flow responses to intra-arterial injection of bradykinin in man. Clin Pharmacol Ther 7: 26–37.PubMedGoogle Scholar
  35. 35.
    Cormia FE, Dougherty JW (1960). Proteolytic activity in development of pain and itching: cutaneous reactions to bradykinin and kallikrein. J Invest Derm 35: 21–26.PubMedGoogle Scholar
  36. 36.
    Guzman F, Braun C, Lim RKS (1962). Visceral pain and the pseudoaffective response to intra-arterial injection of bradykinin and other algesic agents. Arch Int Pharmacodyn 136: 353–384.PubMedGoogle Scholar
  37. 37.
    Lim RKS, Miller DG, Guzman F, Rodgers DW, Wang RW, Chao SK, Shih TY (1967). Pain and analgesia evaluated by intraperitoneal bradykinin-evoked pain method in man. Clin Pharmacol Ther 8: 521–542.PubMedGoogle Scholar
  38. 38.
    Edery H, Lewis GP (1963). Kinin-forming activity and histamine in lymph after tissue injury. J Physiol 169: 568–583.PubMedGoogle Scholar
  39. 39.
    Juan H (1977). Mechanism of action of bradykinin-induced release of prostaglandin E. Naunyn Schmiedeberg Arch Pharmacol 300: 77–85.CrossRefGoogle Scholar
  40. 40.
    Lembeck F, Popper H, Juan H (1976). Release of prostaglandins by bradykinin as an intrinsic mechanism of its algesic effect. Naunyn Schmiedeberg Arch Pharmacol 294: 69–73.CrossRefGoogle Scholar
  41. 41.
    Hori Y, Katori M, Harada Y, Uchida Y, Tanaka K (1986). Potentiation of bradykinin-induced nociceptive response by arachidonate metabolites in dogs. Eur J Pharmacol 132: 47–52.PubMedCrossRefGoogle Scholar
  42. 42.
    Beck PW, Handwerker HO (1974). Bradykinin and serotonin effects on various types of cutaneous nerve fibers. Pflueger Arch 347: 209–222.CrossRefGoogle Scholar
  43. 43.
    Khan AA, Raja SN, Campbell JN, Hartke TV, Meyer RA (1986). Bradykinin sensitizes nociceptors to heat stimuli. Soc Neurosci Abstr 12: 219.Google Scholar
  44. 44.
    Manning DC, Vavrek R, Stewart JM, Snyder SH (1986). Two bradykinin binding sites with picomolar affinities. J Pharmacol Exp Ther 237: 504–512.PubMedGoogle Scholar
  45. 45.
    Regoli D, Barabe J (1980). Pharmacology of bradykinin and related kinins. Pharmacol Rev 32: 1–46.PubMedGoogle Scholar
  46. 46.
    Yano K, Higashida H, Hattori H, Nozawa Y (1985). Bradykinin-induced transient accumulation of inositol trisphosphate in neuron-like cell line NG108–15 cells. FEBS Lett 181: 403–406.PubMedCrossRefGoogle Scholar
  47. 47.
    Braas KM, Manning DC, Perry DC, Snyder SH (1988). Bradykinin analogues: differential agonist and antagonist activities suggesting multiple receptors. Br J Pharmacol 94: 3–5.PubMedGoogle Scholar
  48. 48.
    Snider RM, Richelson E (1984). Bradykinin receptor-mediated cyclic GMP formation in a nerve cell population (murine neuroblastoma clone N 1 E-115). J Neurochem 43: 1749–1754.Google Scholar
  49. 49.
    Steranka LR, Manning DC, DeHaas CJ, Ferkany JW, Borosky SA, Connor JR, Vavrek RJ, Stewart JM, Snyder SH (1988). Bradykinin as a pain mediator: receptors localized to sensory neurons and analgesic actions of antagonists. Proc Natl Acad Sci USA 85: 3245–3249.PubMedCrossRefGoogle Scholar
  50. 50.
    Manning DC, Snyder SH (1986). 41-Bradykinin binding site localization in guinea pig urinary system. In LM Greenbaum, HS Margolius, eds. Kinins IV. Plenum, New York, pp 563–570.Google Scholar
  51. 51.
    Aung-Khin M (1973). The innervation of the ureter. Invest Urol 10: 370–378.PubMedGoogle Scholar
  52. 52.
    Staszewska-Barczak J, Ferreira SH, Vane JR (1976). An excitatory nociceptive cardiac reflex elicited by bradykinin and potentiated by prostaglandins and myocardial ischemia. Cardiovasc Res 10: 314.CrossRefGoogle Scholar
  53. 53.
    Uchida Y, Murao S (1974). Bradykinin-induced excitation of afferent cardiac sympathetic nerve fibers. Jpn Heart J 15: 84–91.PubMedCrossRefGoogle Scholar
  54. 54.
    Kellermeyer RW, Graham RC (1968). Kinins-possible physiologic and pathologic roles in the man. N Engl J Med 279: 859–866.PubMedCrossRefGoogle Scholar
  55. 55.
    Code CF (1965). Histamine and gastric secretion: A later look, 1955–1965. Fed Proc 24: 1311–1321.PubMedGoogle Scholar
  56. 56.
    Vavrek RJ, Stewart JM (1985). Competitive antagonists of bradykinin. Peptides 6: 161–164.PubMedCrossRefGoogle Scholar
  57. 57.
    Steranka LR, DeHaas CJ, Vavrek RJ, Stewart JM, Enna SJ, Snyder SH (1987). Antinociceptive effects of bradykinin antagonists. Eur J Pharmacol 136: 261–262.PubMedCrossRefGoogle Scholar
  58. 58.
    Randall LO, Selitto JJ (1957). A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn 111: 409–418.PubMedGoogle Scholar
  59. 59.
    Ribeiro SA, Corrado AP, Graeff FG (1971). Antinociceptive action of intraventricular bradykinin. Neuropharmacology 10: 725–731.PubMedCrossRefGoogle Scholar
  60. 60.
    Corrado AP, Graeff FG, Ribeiro SA, Riccioppo Neto F (1974). Comparison of effects of bradykinin administered intracarotideally and intraventricularly. Cienc Cult (Sao Paulo) 26: 589–596.Google Scholar
  61. 61.
    Ribeiro SA, Rocha e Silva M (1973). Antinociceptive action of bradykinin and related kinins of larger molecular weight by the intraventricular route. Br J Pharmacol 47: 517–528.PubMedGoogle Scholar
  62. 62.
    Pearson L, Lambert GA, Lang WJ (1969). Centrally mediated cardiovascular and EEG responses to bradykinin and eledoisin. Eur J Pharmacol 8: 153–158.PubMedCrossRefGoogle Scholar
  63. 63.
    Hoffman WE, Schmid PG (1978). Separation of pressor and antidiuretic effects of intraventricular BK. Neuropharmacology 17: 999–1002.PubMedCrossRefGoogle Scholar
  64. 64.
    Kondo K, Okuno T, Konishi K, Saruta T, Kato E (1979). Central and peripheral effects of bradykinin and prostaglandin E2 on blood pressure in conscious rats. Naunyn Schmeideberg Arch Pharmacol 308: 111–115.CrossRefGoogle Scholar
  65. 65.
    Kariya K, Yamauchi A, Chatani Y (1982). Relationship between central actions of bradykinin and prostaglandins in the conscious rat. Neuropharmacology 21: 267–272.PubMedCrossRefGoogle Scholar
  66. 66.
    Lewis RE, Hoffman WE, Phillips MI (1983). Angiotensin II and bradykinin: Interactions between two centrally active peptides. Am J Physiol 244: R285–R291.PubMedGoogle Scholar
  67. 67.
    Correa FMA, Graeff FG (1975). Central site of the hypertensive action of BK. J Pharmacol Exp Ther 192: 670–676.PubMedGoogle Scholar
  68. 68.
    Hod S (1968). The presence of bradykinin-like polypeptides, kinin-releasing and destroying activity in brain. Jpn J Physiol 18: 722–787.Google Scholar
  69. 69.
    Iwata H, Shikimi T, Oka T (1969). Pharmacological significance of peptidase and proteinase in the brain (report 1)-Enzymatic inactivation of bradykinin in rat brain. Biochem Pharmacol 18: 119–128.PubMedCrossRefGoogle Scholar
  70. 70.
    Camagro ACM, Ramalho-Pinto FJ, Greene LJ (1972). Brain peptidase: Conversion and inactivation of kinin hormones. J Neurochem 19: 37–49.CrossRefGoogle Scholar
  71. 71.
    Shikimi T, Kerna R, Matsumoto M, Yamahata Y, Miyata S (1973). Studies on kinin-like substances in brain. Biochem Pharmacol 22: 567–573.PubMedCrossRefGoogle Scholar
  72. 72.
    Kariya K, Iwaki H, Ihda M, Maruta E, Murase M (1981). Central actions of bradykinin. I. Electroencephalogram of bradykinin and its degradation system in rat brain. Jpn. J. Pharmacol. 31: 261–267.PubMedCrossRefGoogle Scholar
  73. 73.
    Kariya K, Yamauchi A, Hattori S, Tsuda Y, Okada Y (1982). The disappearance of intraventricular bradykinin in the brain of the conscious rat. Biochem Biophys Res Commun 107: 1461–1466.PubMedCrossRefGoogle Scholar
  74. 74.
    Chao J, Woodley C, Chao L, Margolius HS (1983). Identification of tissue kallikrein in brain and in the cell-free translation product encoded by brain mRNA. J Biol Chem 258: 15173–15178.PubMedGoogle Scholar
  75. 75.
    Inouye A, Kataoka K, Tsujioka T (1961). On a kinin-like substance in nervous tissue extracts treated with trypsin. Jpn J Physiol 11: 319–334.PubMedCrossRefGoogle Scholar
  76. 76.
    Werle E, Zach P (1970). Verteilung von Kininogen in Serum and Geweben bei Ratten und anderen Saugetieren. Z Klin Chem 8: 186–189.Google Scholar
  77. 77.
    Pela IR, Gardy-Levassort C, Lechat P, Rocha e Silva M (1975). Brain kinins and fever induced by bacterial pyrogens in rabbits. J Pharm Pharmacol 27: 793–794.PubMedCrossRefGoogle Scholar
  78. 78.
    Correa FMA, Innis RB, Uhl GR, Snyder SH (1979). Bradykinin-like immunoreactive neuronal systems localized histochemically in rat brain. Proc Natl Acad Sci USA 76: 1489–1493.PubMedCrossRefGoogle Scholar
  79. 79.
    Perry DC, Snyder SH (1984). Identification of bradykinin in mammalian brain. J Neurochem 43: 1072–1080.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1989

Authors and Affiliations

  • Solomon H. Snyder
  • Donald C. Manning
  • Larry R. Steranka

There are no affiliations available

Personalised recommendations